Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease-Reference-Cited by-同舟云学术

Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease

Published:2022-02-16 Issue:5 Volume:24 Page:827-837
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Chertow Glenn M.¹^ORCID,Vart Priya²,Jongs Niels²,Langkilde Anna Maria³,McMurray John J. V.⁴^ORCID,Correa‐Rotter Ricardo⁵,Rossing Peter⁶⁷,Sjöström C. David³,Stefansson Bergur V.³,Toto Robert D.⁸,Wheeler David C.⁹,Heerspink Hiddo J. L.²¹⁰^ORCID

Affiliation:

1. Departments of Medicine and Epidemiology and Population Health Stanford University School of Medicine Stanford California USA

2. Department of Clinical Pharmacy and Pharmacology, University of Groningen University Medical Center Groningen Groningen The Netherlands

3. Late‐Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden

4. Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UK

5. The National Medical Science and Nutrition Institute Salvador Zubiran Mexico City Mexico

6. Steno Diabetes Center Copenhagen Gentofte Denmark

7. Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

8. Department of Internal Medicine UT Southwestern Medical Center Dallas Texas USA

9. Department of Renal Medicine University College London London UK

10. The George Institute for Global Health Sydney Australia

Funder

AstraZeneca Pharma Poland

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14641

Reference39 articles.

1. Obesity: global epidemiology and pathogenesis

2. Organisation for Economic Co‐operation and DevelopmentObesity update 2017.https://www.oecd.org/els/health-systems/Obesity-Update-2017.pdf. Accessed September 15 2021.

3. World Obesity FederationPrevalence of Obesity.https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity. Accessed September 15 2021.

4. World Health Organization: Obesity and Overweight factsheet.https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed September 15 2021.

5. Global, regional and time-trend prevalence of central obesity: a systematic review and meta-analysis of 13.2 million subjects

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07

2. Obesidad y enfermedad cardiovascular y renal. Posicionamiento de las Asociaciones de Cardiología Preventiva, Cardiología Clínica e Insuficiencia Cardiaca de la SEC;REC: CardioClinics;2024-07

3. Targeted identification of risk and treatment of diabetic kidney disease;Nature Reviews Nephrology;2023-12-01

4. Environmental Epigenetics and Obesity;Epigenetics - Regulation and New Perspectives;2023-11-08